

**Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease**


Aline Floch,<sup>1</sup> Alexandre Morel,<sup>2</sup> Fabian Zanchetta-Balint,<sup>2</sup> Catherine Cordonnier-Jourdin,<sup>3</sup> Slimane Allali,<sup>4</sup> Maximilien Grall,<sup>5</sup> Ghislaine Ithier,<sup>6</sup> Benjamin Carpentier,<sup>7</sup> Sadaf Pakdaman,<sup>1</sup> Jean-Claude Merle,<sup>8</sup> Radjiv Goulabchand,<sup>9</sup> Tackwa Khalifeh,<sup>10</sup> Ana Berceanu,<sup>11</sup> Cécile Helmer,<sup>12</sup> Christelle Chantalat-Auger,<sup>13</sup> Véronique Frémeaux-Bacchi,<sup>14</sup> Marc Michel,<sup>15</sup> Mariane de Montalembert,<sup>4</sup> Armand Mekontso-Dessap,<sup>16</sup> France Pirenne,<sup>1</sup> Anoosha Habibi<sup>2</sup> and Pablo Bartolucci<sup>2</sup>

<sup>1</sup>Etablissement français du sang Ile de France, INSERM Unit 955, Laboratory of Excellence GR-Ex, Mondor Institute of Biomedical Research, Paris-Est Creteil University, Creteil; <sup>2</sup>French Sickle Cell Referral Center, Henri Mondor Teaching Hospital, Assistance Publique-Hopitaux de Paris, Laboratory of Excellence GR-Ex, INSERM Unit 955, Mondor Institute of Biomedical Research, Paris-Est Creteil University, Creteil; <sup>3</sup>Department of Pharmacy, Henri Mondor Teaching Hospital, Assistance Publique-Hopitaux de Paris; <sup>4</sup>Department of Pediatrics, Necker Hospital for Sick Children, Assistance Publique-Hopitaux de Paris, Laboratory of Excellence GR-Ex, Paris Descartes University, Paris; <sup>5</sup>Department of Internal Medicine, Rouen Teaching Hospital, Rouen; <sup>6</sup>Hematology Unit, Reference Center of Sickle Cell Disease, Robert Debré Hospital, Assistance Publique-Hopitaux de Paris, Paris; <sup>7</sup>Department of Hematology, Saint Vincent de Paul Hospital, Lille Catholic University, Lille; <sup>8</sup>Department of Anesthesia and Surgical Intensive Care, Liver Intensive Care Unit, Henri Mondor Teaching Hospital, Assistance Publique-Hopitaux de Paris, Creteil; <sup>9</sup>Department of Internal Medicine-Multiorganic Diseases, Local Referral Center for Autoimmune Diseases, Saint-Eloi Hospital, Montpellier University, Montpellier; <sup>10</sup>Pediatric Medical-Surgical Department, Poitiers Teaching Hospital, Poitiers, France; <sup>11</sup>Intensive Care Hematology Unit, Besancon Teaching Hospital, Besancon; <sup>12</sup>Etablissement français du sang Auvergne-Rhône Alpes, Grenoble; <sup>13</sup>Department of Internal Medicine, Bicetre Teaching Hospital, Assistance Publique-Hopitaux de Paris, Université Paris 11, Le Kremlin-Bicetre, Paris; <sup>14</sup>Laboratory of Immunology, European Georges Pompidou Hospital, Assistance Publique-Hopitaux de Paris, Mixed Health Research Unit INSERM 872, Cordeliers Research Center, Paris; <sup>15</sup>Department of Internal Medicine, National Referral Center for Immune Cytopenias, Henri Mondor Teaching Hospital, Assistance Publique-Hopitaux de Paris, Creteil and <sup>16</sup>Medical Intensive Care Unit, Henri Mondor Teaching Hospital, Assistance Publique-Hopitaux de Paris, Creteil, France

Correspondence: PABLO BARTOLUCCI - [pablo.bartolucci@aphp.fer](mailto:pablo.bartolucci@aphp.fer)

[doi:10.3324/haematol.2020.253856](https://doi.org/10.3324/haematol.2020.253856)

**Supplemental Data Legend:** Figures for individual patient timelines, with main events. The scales are the same for all patients, to facilitate comparison. The timelines are discontinuous for longer follow-up periods, to maintain the same scale throughout.



# Patient 1A



Notable events:

Day -8: hemodynamic failure, acute cor-pulmonale



Day -7: kidney and liver failure

Complement analysis on day 7:

- C3: 1270 mg/L (N=[660-1250])
- C4: 257 mg/L (N=[93-380])
- Soluble C5B9: 1797 mg/L (N=<450)



# Patient 2B





# Patient 3C

Notable events:

Day -1: hemodynamic, kidney and liver failure



Day 0: respiratory failure

Day 1: death



# Patient 4D

Notable events:  
Day -1: kidney failure





# Patient 5E

Notable events:

Day -1: respiratory failure, acute cor-pulmonale

Day -7: kidney and liver failure



Day 12: sepsis



# Patient 6F

Complement analysis:



	CH50 (%) N=[70-130}	C3 (mg/L) N=[660-1250}	C4 (mg/L) N=[93-380}	Soluble C5B9 (mg/L) N<450
Day 0	124	1080	266	856
Day 2	23	1030	283	1223
Day 14	30	1050	248	1406





# Patient 7G

Notable events:  
 Day -1: respiratory failure  
 Day 2: sepsis



# Patient 8H

Notable events:

Day -1: liver failure

Day 0: kidney, respiratory, hemodynamic failure

Day 1: first liver transplantation

Day 3: liver failure

Day 4: second liver transplantation


Day 14: sepsis

Day 15: death

Complement analysis:



	C3 (mg/L) N=[660-1250]	C4 (mg/L) N=[93-380]	Soluble C5B9 (mg/L) N<450
Day 0	1070	220	1527
Day 4	313	104	296
Day 6	359	129	224
Day 9	928	526	355
Day 13	1210	290	509

— Total Hb (g/L)	△ 1 pRBC transfusion
- - - HbA (g/L)	Anti-C5 infusion
— LDH (IU/L)	* Organ failure
- - - Total bilirubin (µmol/L)	Hepatic transplantation
— Reticulocyte count (10 <sup>9</sup> /L) (refer to the black axis)	Death





# Patient 91

Notable events:  
 Day 0 (before anti-C5): acute cor-pulmonale,  
 liver, kidney, hemodynamic failure





# Patient 10J



Complement activity CH50 <20% on day 1 and 4 (N=[70-130])





# Patient 11K



# Patient 12L





# Patient 13M





# Patient 14N

Notable events:  
 Day 0 (a few hours after anti-C5): hemodynamic failure,  
 acute cor-pulmonale  
 Day 1: respiratory failure





# Patient 150



# Patient 16P

Much of the timeline is truncated to keep the same scale for all graphs.


Notable events:

- Day -10: liver failure
- Day 20: sepsis
- Day 42: liver transplantation
- Day 86: graft infection
- Day 89: death

Complement analysis:



	C3 (g/L) N=[0,90-1,80]	C4 (g/L) N=[0,10-0,40]
Day 3	0,57	0,09
Day 8	0,42	0,07
Day 10	0,72	0,13
Day 15	0,99	0,18
Day 21	1,1	0,2

<span style="color: red;">—</span> Total Hb (g/L)	<span style="color: red;">△</span> 1 pRBC transfusion
<span style="color: red;">- - -</span> HbA (g/L)	<span style="color: green;"> </span> Anti-C5 infusion
<span style="color: blue;">—</span> LDH (IU/L)	<span style="color: black;">*</span> Organ failure
<span style="color: black;">- - -</span> Total bilirubin (μmol/L)	<span style="color: red;"> </span> Hepatic transplantation
<span style="color: yellow;">—</span> Reticulocyte count (10 <sup>9</sup> /L) <i>(refer to the black axis)</i>	<span style="color: black;"> </span> Death



# Patient 17Q

Notable events:  
Day -1: kidney and respiratory failure



# Patient 18R

